ArticleTherapeutic advances in medical oncology2024

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.

Guojin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.